Navigation Links
Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
Date:7/24/2009

Terumo Cardiovascular Systems Corporation manufactures and markets medical devices for the global cardiac surgery market and is the U.S. distributor for Vascutek(R) Vascular Grafts. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; and Ashland, Massachusetts. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiac and vascular specialties, including Terumo Heart Inc., developer of a ventricular assist device and Vascutek Ltd., a global leader in the design and manufacture of vascular grafts. For more information, visit www.terumo-cvs.com.

Terumo Corporation is a premier global medical device company with annual sales of more than three billion dollars for the year ending March 31, 2009. Founded in 1921, the company develops, manufactures and distributes world-class medical devices for use in cardiothoracic surgery, interventional procedures, transfusion medicine, and needle and syringe products. For more information, visit www.terumo.co.jp/English/index.html.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
2. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
3. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
4. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
5. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
6. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
7. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
8. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
9. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. CardioVascularCS.Org, a division of EndoVascular Forum, Inc., Partners with Complex Interventional Cardiovascular Therapy (CICT) to Extend Electronic Medical Care Advancement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah Associates ... providing a summary of the 2015 marketplace exchange ... trends.  According to a recent ... and Evaluation, Department of Health and Human Services) ... in individual medical plans through the Marketplace as ...
(Date:12/22/2014)... , Dec. 22, 2014  Pfenex Inc. (NYSE MKT: ... anthrax vaccine, has been filed and is now open ... by the Department of Health and Human Services (HHS), ... "We are extremely pleased to have the ... This represents a significant milestone in our company,s partnership ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... , ... Corp. (CVSL.OB), a leading developer of advanced,cardiovascular surgery technology, today ... stock split, in the form of a,stock dividend, payable to ... The Company will announce in due course the estimated date ...
... Adults are more likely to lose their vision than be ... vision are one in three, whereas the odds of a man developing ... breast cancer are one in nine. Vision loss threatens the overall ... inability to complete daily tasks. , Vision loss in adults is often ...
Cached Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2
(Date:12/26/2014)... 26, 2014 Cooking and warming ... out of 5. This score reflects slightly positive negotiation ... product specialization, low switching costs and a low level ... the low availability of substitutes for cooking and warming ... steel and aluminum, key inputs in the production process ...
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... OAK BROOK, Ill., April 22 The ... of Minnesota have agreed to conditions for ... receive certain services from DeCare Dental following ... certain business functions that DeCare previously performed ...
... patient medical bill clearinghouse is set to help more than 50 ... patient medical debt. IOUSOS™, Powered by GlobeFunder and GlobalTech Collection ... way to deal with aged, unpaid patient bills now totaling an ... ...
... of Driver Technology to Power Artificial Heart Presented at ISHLT ... ... (Vocus) April 22, 2009 -- On April 22-25, SynCardia Systems, ... introduced the new 12-lb Freedom™ discharge driver at the International ...
... Illinois-based leader in physical therapy, fitness, and performance services, recently reached ... Chicago,s Hyde Park neighborhood and 51st center in suburban Naperville. ... ... AthletiCo , an Illinois-based leader in physical therapy, fitness, ...
... clinical supply chain management, announced today that Daniel C. Lubin, a Managing ... www.mhsinc.com , ... Fairfield, Connecticut (PRWEB) April 22, 2009-- ... clinical supply chain management, announced today that Daniel C. Lubin, a Managing ...
... to providing people with skin care information from ... and helpful insights are provided by skin care ... cosmetic dermatology. The content is written by experts ... of practical advice. Key portions of the service ...
Cached Medicine News:Health News:Delta Dental Plans Association and Delta Dental of Minnesota Agree to Conditions Regarding Supplier 2Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 2Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 3Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 4Health News:SynCardia Introduces New 12-lb Freedom Discharge Driver ,Designed to Provide Quality 'Lifestyle' for Total Artificial Heart Patients 2Health News:Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center 2Health News:Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center 3Health News:Daniel C. Lubin Joins Management Health Solutions, Inc. Board of Directors 2Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
Medicine Products: